US Stock MarketDetailed Quotes
ANAB AnaptysBio
- 25.120
- -0.130-0.51%
Close Nov 27 16:00 ET
- 25.120
- 0.0000.00%
Post 20:01 ET
764.37MMarket Cap-4152P/E (TTM)
26.510High24.730Low416.54KVolume25.610Open25.250Pre Close10.57MTurnover2.10%Turnover RatioLossP/E (Static)30.43MShares41.30852wk High9.06P/B499.43MFloat Cap14.69852wk Low--Dividend TTM19.88MShs Float134.000Historical High--Div YieldTTM7.05%Amplitude10.000Historical Low25.376Avg Price1Lot Size
AnaptysBio Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 72.34%-10.09M | 16.08%-21.32M | -51.63%-37.25M | -64.15%-120.8M | -221.47%-34.35M | -105.52%-36.47M | -5.23%-25.41M | -16.91%-24.57M | -60.26%-73.59M | 57.77%-10.69M |
| Net income from continuing operations | 11.95%-32.85M | -17.10%-46.66M | 0.72%-43.94M | -27.11%-163.62M | -59.81%-42.21M | -11.36%-37.31M | -22.40%-39.85M | -22.07%-44.26M | -122.72%-128.72M | 18.82%-26.41M |
| Depreciation and amortization | 0.68%596K | 1.36%595K | 2.02%605K | 1.76%2.38M | -0.33%604K | 1.20%592K | 2.80%587K | 3.49%593K | 11.72%2.34M | 57.40%606K |
| Other non cash items | 247.84%15.41M | 151.33%10.95M | 45.69%6.32M | -14.33%18.08M | 16.63%4.96M | -27.78%4.43M | -25.73%4.36M | -10.67%4.34M | 1,355.72%21.11M | --4.25M |
| Change In working capital | 112.54%1.13M | 168.65%8.72M | -191.51%-7.4M | -104.74%-324K | -144.97%-2.66M | -353.75%-9M | 171.69%3.25M | 323.29%8.09M | 191.32%6.84M | 346.30%5.91M |
| -Change in receivables | -3,564.37%-3.19M | -15.61%-1.92M | -128.85%-238K | -900.37%-5.43M | -1,398.74%-3.58M | 40.82%-87K | -1,381.25%-1.66M | -131.11%-104K | 38.01%-543K | -107.83%-239K |
| -Change in prepaid assets | 124.24%1.41M | 337.23%3.07M | -3,170.59%-1.57M | -415.87%-4.19M | 66.74%2.84M | -305.46%-5.8M | 68.63%-1.29M | 104.18%51K | 54.86%-813K | -74.70%1.71M |
| -Change in payables and accrued expense | 224.50%3.36M | 21.39%8.02M | -160.61%-5.17M | 12.76%10.94M | -131.00%-1.5M | -314.96%-2.7M | 8,706.67%6.61M | 141.32%8.53M | 304.64%9.7M | 190.81%4.83M |
| -Change in other current liabilities | -8.13%-452K | -8.60%-442K | -8.95%-426K | -8.70%-1.64M | -7.97%-420K | -9.14%-418K | -8.82%-407K | -8.91%-391K | -1,990.28%-1.51M | -2,045.00%-389K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 72.34%-10.09M | 16.08%-21.32M | -51.63%-37.25M | -64.15%-120.8M | -221.47%-34.35M | -105.52%-36.47M | -5.23%-25.41M | -16.91%-24.57M | -60.26%-73.59M | 57.77%-10.69M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 91.35%58.62M | 88.06%-2.44M | -19.65%68.62M | 136.66%144.75M | 128.77%49.18M | 194.45%30.64M | 71.19%-20.46M | 127.29%85.4M | -1,116.72%-394.85M | 132.23%21.5M |
| Net PPE purchase and sale | 78.40%-35K | 82.63%-33K | 84.57%-27K | -125.42%-807K | -60.00%-280K | -224.00%-162K | -143.59%-190K | -218.18%-175K | 73.50%-358K | -1,150.00%-175K |
| Net investment purchase and sale | 90.46%58.66M | 88.11%-2.41M | -19.78%68.64M | 136.90%145.56M | 128.21%49.46M | 195.10%30.8M | 71.42%-20.27M | 127.35%85.57M | -1,081.65%-394.49M | 132.50%21.67M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 91.35%58.62M | 88.06%-2.44M | -19.65%68.62M | 136.66%144.75M | 128.77%49.18M | 194.45%30.64M | 71.19%-20.46M | 127.29%85.4M | -1,116.72%-394.85M | 132.23%21.5M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 2,418.68%71.23M | 410.48%41.89M | 63.72%-13.63M | -234.71%-59.3M | -364.70%-5.16M | -108.30%-3.07M | -3,223.15%-13.49M | -915.23%-37.57M | -82.55%44.02M | -99.22%1.95M |
| Net common stock issuance | 61,460.63%98.5M | 108.37%979K | 102.24%811K | -501.86%-47.53M | -92.28%264K | -94.07%160K | -1,451.56%-11.69M | -848.58%-36.26M | 363.26%11.83M | 114.90%3.42M |
| Proceeds from stock option exercised by employees | --0 | --0 | ---7.5M | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Net other financing activities | -743.66%-27.27M | 2,371.57%40.91M | -428.56%-6.94M | -136.56%-11.77M | -268.91%-5.42M | -109.42%-3.23M | -315.94%-1.8M | -458.72%-1.31M | -87.11%32.19M | ---1.47M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 2,418.68%71.23M | 410.48%41.89M | 63.72%-13.63M | -234.71%-59.3M | -364.70%-5.16M | -108.30%-3.07M | -3,223.15%-13.49M | -915.23%-37.57M | -82.55%44.02M | -99.22%1.95M |
| Net cash flow | ||||||||||
| Beginning cash position | 104.00%71.82M | -43.22%53.7M | -49.56%35.97M | -85.62%71.31M | -55.09%26.3M | -50.90%35.21M | -43.18%94.56M | -85.62%71.31M | 97.88%495.73M | -82.60%58.55M |
| Current changes in cash | 1,443.96%119.76M | 130.54%18.13M | -23.76%17.73M | 91.67%-35.34M | -24.22%9.67M | 32.26%-8.91M | 37.33%-59.36M | 107.06%23.25M | -273.08%-424.42M | -91.99%12.76M |
| End cash Position | 628.58%191.58M | 104.00%71.82M | -43.22%53.7M | -49.56%35.97M | -49.56%35.97M | -55.09%26.3M | -50.90%35.21M | -43.18%94.56M | -85.62%71.31M | -85.62%71.31M |
| Free cash flow | 72.36%-10.13M | 16.58%-21.36M | -50.67%-37.28M | -64.44%-121.61M | -218.87%-34.63M | -105.85%-36.64M | -5.67%-25.6M | -17.44%-24.74M | -56.39%-73.95M | 57.10%-10.86M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data